Haleon sale funds new acquisition

PFIZER INC. $49 is a buy. The prescription drugmaker (New York symbol PFE; Manufacturing & Industry sector; Shares outstanding: 5.6 billion; Market cap: $274.4 billion; Dividend yield: 3.3%; Takeover Target Rating: Medium; www.pfizer.com) merged its consumer drug business with GlaxoSmithKline (New York symbol GSK) in 2019.
Glaxo now plans to… Read More

Drugmaker opts for spinoff over sale

Pharmaceutical giant GlaxoSmithKline recently rejected a takeover offer from Unilever for its consumer drug business and will continue with its original plan to spin it off as a separate company.
The spinoff will let Glaxo better focus on its main prescription drug and vaccine operations. We… Read More

Spinoff spotlight

GLAXOSMITHKLINE PLC ADRs $46 is a spinoff buy. The company (New York symbol GSK; Manufacturing sector; ADRs outstanding: 2.7 billion; Market cap: $124.2 billion; Dividend yield: 4.7%; Takeover Target Rating: Medium; www.gsk.com) is a U.K.-based global healthcare firm that develops and sells products in three main markets: pharmaceuticals (50%… Read More

Latest pharma spinoff should pay off

Johnson & Johnson recently announced that it would spin off its consumer drug business as a separate firm. This follows several other big pharmaceutical firms, including Pfizer, GlaxoSmithKline and Merck, that have completed similar spinoffs.
The breakup will let Johnson & Johnson focus on its more-profitable… Read More

Spinoff and activist will benefit Glaxo

Pharmaceutical giant GlaxoSmithKline has stayed in an narrow range of $33 to $48 in the past five years as it struggled with high costs and poor acquisitions.
The company now plans to re energize its growth by spinning off its consumer business as a separate company… Read More